Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses (Q44351492)

2 December 2017

title

Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses (English)

1 reference

Mycobacterium tuberculosis

2 December 2017

main subject

0 references

1 reference

Ying Yin

1

1 reference

2 December 2017

Hao Li

2

1 reference

2 December 2017

Shipo Wu

3

1 reference

2 December 2017

Dayong Dong

4

1 reference

2 December 2017

Jun Zhang

5

1 reference

2 December 2017

Ling Fu

6

1 reference

2 December 2017

Junjie Xu

7

1 reference

2 December 2017

Wei Chen

8

1 reference

2 December 2017

language of work or name

English

0 references

publication date

29 June 2011

1 reference

2 December 2017

1 reference

2 December 2017

volume

29

1 reference

2 December 2017

issue

34

1 reference

2 December 2017

page(s)

5645-5651

1 reference

Current status of TB vaccines

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Tuberculosis vaccine research: the impact of immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

TB vaccines: current status and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Novel tuberculosis vaccines on the horizon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Tuberculosis vaccines—a new kid on the block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

ESAT-6 proteins: protective antigens and virulence factors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex. Implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

HBV core particles as a carrier for B cell/T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Universal influenza A vaccine: optimization of M2-based constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

A "universal" human influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Use of hepadnavirus core proteins as vaccine platforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Immunological properties of hepatitis B core antigen fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

The protective role of antibody responses during Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

The crystal structure of the human hepatitis B virus capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Interaction of the hepatitis B core antigen and the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Evidence for pore formation in host cell membranes by ESX-1-secreted ESAT-6 and its role in Mycobacterium marinum escape from the vacuole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Combinatorial approach to hepadnavirus-like particle vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Comparative antigenicity and immunogenicity of hepadnavirus core proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.06.012

10.1016/J.VACCINE.2011.06.012

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference